Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 9:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 311 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Molecular diagnostic testing Clear all
Completed No phase listed Observational Accepts healthy volunteers

Molecular Markers in Predicting Lung Cancer Development Using Tissue Samples From Healthy Participants

NCT00899457
View directory record Official record
Conditions
Healthy, no Evidence of Disease, Lung Cancer
Interventions
proteomic profiling, biologic sample preservation procedure, laboratory biomarker analysis, bronchoscopy
Genetic · Other · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Oct 18, 2026, 9:50 AM EDT
Recruiting Phase 2 Interventional

Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

NCT07282912
View directory record Official record
Conditions
Foregut Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma, Pancreas Adenocarcinoma, Duodenal Adenocarcinoma, Ampullary Adenocarcinoma, Gallbladder Adenocarcinoma, Intra - and Extrahepatic Cholangiocarcinoma
Interventions
Sequential cytoreductive intervention, Signatera Genome ultra-sensitive ctDNA blood test
Procedure · Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 18, 2026, 9:50 AM EDT
Completed Phase 1 Interventional

Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma

NCT00822848
View directory record Official record
Conditions
Sarcoma
Interventions
epirubicin hydrochloride, ifosfamide, sorafenib tosylate, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, hypofractionated radiation therapy
Drug · Other · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
15 Years to 120 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 18, 2026, 9:50 AM EDT
Completed Early Phase 1 Interventional

MUC1 Vaccine for Triple-negative Breast Cancer

NCT00986609
View directory record Official record
Conditions
Breast Cancer, Inflammatory Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-negative Breast Cancer
Interventions
MUC-1 peptide vaccine, poly ICLC, MUC1 peptide-poly-ICLC adjuvant vaccine, laboratory biomarker analysis, enzyme-linked immunosorbent assay, flow cytometry
Biological · Other
Lead sponsor
Joseph Baar, MD, PhD
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Oct 18, 2026, 9:50 AM EDT
Recruiting Phase 2 Interventional

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

NCT06311214
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Electronic Health Record Review, Enfortumab Vedotin, Immunohistochemistry Staining Method, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sacituzumab Govitecan, Trastuzumab Deruxtecan
Procedure · Other · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
27
States / cities
Duarte, California • Encinitas, California • Irvine, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 18, 2026, 9:50 AM EDT
Completed Phase 1 Interventional Results available

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma

NCT00398138
View directory record Official record
Conditions
Leukemia, Lung Cancer, Malignant Mesothelioma, Myelodysplastic Syndromes, Primary Peritoneal Cavity Cancer
Interventions
WT-1 analog peptide vaccine, incomplete Freund's adjuvant, sargramostim, polymerase chain reaction, flow cytometry, immunoenzyme technique
Biological · Genetic · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Oct 18, 2026, 9:50 AM EDT
Not listed Not applicable Interventional

Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer

NCT00436709
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, pegfilgrastim, cyclophosphamide, doxorubicin hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation, flow cytometry, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, adjuvant therapy, immunoscintigraphy
Biological · Drug · Other + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 18, 2026, 9:50 AM EDT
Active, not recruiting Phase 2 Interventional

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

NCT03817398
View directory record Official record
Conditions
Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
Interventions
Biospecimen Collection, Drug Withdrawn, Quality-of-Life Assessment, Questionnaire Administration, Tyrosine Kinase Inhibitor
Procedure · Other · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 25 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
157
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 123 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 18, 2026, 9:50 AM EDT
Completed Phase 1 Interventional

Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma

NCT00568763
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
sargramostim, immunoenzyme technique, immunohistochemistry staining method, immunologic technique, laboratory biomarker analysis, biopsy, cryosurgery, radiofrequency ablation
Biological · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 18, 2026, 9:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Study of a Diagnostic Device for NG, TV and CT in Women

NCT03852316
View directory record Official record
Conditions
Chlamydial Infection, Gonococcal Infection, Trichomoniasis
Interventions
Click Device
Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
14 Years to 99 Years · Female only
Enrollment
1,585 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Oct 18, 2026, 9:50 AM EDT
Completed Phase 2 Interventional Results available

Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck

NCT00720304
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
docetaxel, erlotinib hydrochloride, fluorescence in situ hybridization, polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, therapeutic conventional surgery, intensity-modulated radiation therapy, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 18, 2026, 9:50 AM EDT
Recruiting No phase listed Observational

A Study to Evaluate the Safety and Efficacy of Intracranial Venous Blood Sampling for Liquid Biopsy in the Diagnosis of Brain Cancers

NCT07467109
View directory record Official record
Conditions
Intracranial Venous Blood, Brain Cancers, Liquid Biopsy, Evaluate the Safety
Interventions
blood sampling
Diagnostic Test
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 18, 2026, 9:50 AM EDT
Completed No phase listed Observational

Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer

NCT00897650
View directory record Official record
Conditions
Lung Cancer
Interventions
DNA/RNA sequencing and expression levels, Protein expression analysis, Lung tumor biopsy, Blood sample
Genetic · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Up to 120 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 18, 2026, 9:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Development of a Newborn Screening Assay for Angelman Syndrome and Prader-Willi Syndrome

NCT05783791
View directory record Official record
Conditions
Angelman Syndrome, Prader-Willi Syndrome
Interventions
Newborn Screening Assay
Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Not listed
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 18, 2026, 9:50 AM EDT
Recruiting No phase listed Observational

Serum Inflammatory Protein Concentration During Dental Treatment

NCT07468929
View directory record Official record
Conditions
Periodontal Disease, Periodontal Surgery
Interventions
Blood samples for inflammatory markers, periodontal surgery, Periodontal maintenance, Non-surgical deep cleaning
Other · Procedure
Lead sponsor
Ohio State University
Other
Eligibility
21 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 18, 2026, 9:50 AM EDT
Not yet recruiting Not applicable Interventional

Usability and Clinical Validation of the Flu A/B/COVID-19 + RSV Multiplex Rapid Test

NCT07875270
View directory record Official record
Conditions
SARS-CoV-2 Infection, Influenza A, Influenza B, RSV
Interventions
Flu A/B/COVID-19 + RSV Multiplex Rapid Test
Device
Lead sponsor
CorDx, Inc.
Industry
Eligibility
6 Months and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Alpharetta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 18, 2026, 9:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

PET/CT Quantitative Assessment of Myocardial Blood Flow Changes in Oncologic Patients Receiving Checkpoint Inhibitor Therapy

NCT04538950
View directory record Official record
Conditions
Cancer
Interventions
PET/CT, radioactive drug (tracer)
Diagnostic Test · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 18, 2026, 9:50 AM EDT
Active, not recruiting Not applicable Interventional

Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative

NCT02276443
View directory record Official record
Conditions
Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions
Chemotherapy, Immunotherapy, Laboratory Biomarker Analysis, Lymph Node Biopsy, Ultrasonography
Drug · Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
798 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
5
States / cities
Conroe, Texas • Houston, Texas • League City, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 18, 2026, 9:50 AM EDT
Withdrawn Phase 1 Interventional

Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer

NCT01219907
View directory record Official record
Conditions
HER2-positive Breast Cancer, Male Breast Cancer, Stage IV Breast Cancer
Interventions
HER-2/neu peptide vaccine, cyclophosphamide, ex vivo-expanded HER2-specific T cells, laboratory biomarker analysis, flow cytometry, immunoenzyme technique
Biological · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 17, 2013 · Synced Oct 18, 2026, 9:50 AM EDT
Completed No phase listed Observational

Anti-IMP3 Autoantibody and MicroRNA Signature Blood Tests in Finding Metastasis in Patients With Localized or Metastatic Kidney Cancer

NCT00806650
View directory record Official record
Conditions
Kidney Cancer
Interventions
gene expression analysis, protein expression analysis, diagnostic laboratory biomarker analysis, immunoenzyme technique, immunohistochemistry staining method
Genetic · Diagnostic Test · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Not listed
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 18, 2026, 9:50 AM EDT
Active, not recruiting No phase listed Observational

Molecular Assessment and Profiling of Liver Transplant Recipients

NCT04793360
View directory record Official record
Conditions
Liver Transplantation, Biomarkers
Interventions
LiverCare
Device
Lead sponsor
CareDx
Industry
Eligibility
12 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
26
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 18, 2026, 9:50 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Genetic Mechanism of Conserved Ancestral Haplotype in SCA10

NCT04495426
View directory record Official record
Conditions
Spinocerebellar Ataxia Type 10
Interventions
Non-interventional study
Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Oct 18, 2026, 9:50 AM EDT
Terminated Phase 2 Interventional Results available

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

NCT06630325
View directory record Official record
Conditions
Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions
Abemaciclib, Biopsy, Bone Scan, Echocardiography, Exemestane, Gemcitabine, Letrozole, Multigated Acquisition Scan, Osimertinib, Pemetrexed, Survey Administration, Tamoxifen, Biospecimen Collection
Drug · Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 18, 2026, 9:50 AM EDT
Completed Early Phase 1 Interventional

NIH CCR2 AAA Study

NCT04586452
View directory record Official record
Conditions
Abdominal Aortic Aneurysm (AAA), No Abdominal Aortic Aneurysm (Non-AAA)
Interventions
AAA Group (Aim 3A), Non-AAA Group, Ex Vivo Human AAA Specimens (Aim 2A), Relationship between radiotracer and CCR2 (Aim 2B), AAA Group (Aim 3B-Reproducibility)
Diagnostic Test · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 18, 2026, 9:50 AM EDT